Annual General Meeting 2016 Dr James Campbell CEO Safe harbour - PowerPoint PPT Presentation

Annual General Meeting 2016 Dr James Campbell CEO

Safe harbour statement The following material is for general informa4on purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Patrys nor any other en4ty or person in or associated with the Patrys group of companies guarantees any return (whether capital or income) or generally the performance of Patrys or the price at which its securi4es may trade. In par4cular, this presenta4on is not a recommenda4on, offer or invita4on to subscribe for or purchase Patrys securi4es. It is not for general distribu4on or third party reliance or use. While it has been prepared from sources Patrys believe to be reliable, Patrys cannot guarantee its accuracy or completeness and undertakes no obliga4on to advise of changes or updates to any such materials. These materials are not exhaus4ve of all of the informa4on a poten4al investor or their professional adviser would require. Nor do these materials take into account any specific objec4ves, financial situa4on or needs of investors. In addi4on, the past performance of Patrys cannot be assumed as indica4ve of the future performance of the company. For these and other reasons, before making any investment decision regarding Patrys securi4es you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those ac4ng without such advice do so at their own risk. Where this presenta4on does contain any forward looking statements, those statements are only made as the date of the presenta4on and are to be considered “at-risk statements” not to be relied upon as they are subject to further research and to known and unknown risks, uncertain4es and other factors that may lead to actual results differing from any forward looking statement. This is par4cularly the case with companies such as Patrys which operate in the field of researching, discovering, developing, and commercialising poten4al drugs intended for safe and effec4ve for human treatments or therapies. 2 Annual General Meeting 2016 2

Vision Patrys is a biopharmaceutical company devoted to the development and commercialisation of novel antibody technologies to improve the clinical outcomes for cancer patients Annual General Meeting 2016 3

Snapshot Exci4ng an4body (Ab) Deoxymabs - in-licensed nuclear-penetra4ng Abs from Yale University • plaWorms and pipeline IgM plaWorm showing safety and signals of clinical efficacy • Both plaWorms offer mul4ple opportuni4es for development • Ability to generate new intellectual property • Good news flow Preclinical tes4ng of mul4ple Deoxymab 3E10 candidates • expected in 2017 Lead candidate selec4on for Deoxymab 3E10 program • Preclinical data and publica4ons on Abs and targets • Ongoing development of PAT-SC1 (via strategic alliance) • Addi4onal alliances and collabora4ons • Good cash runway Strong cash posi4on with streamlined opera4ons and low cash burn • Proven Board and Significant experience in developing an4-cancer drugs • management Significant exper4se in capital-raising and deal-making • Annual General Meeting 2016 4

Year in review • Completed a year of restructuring, rebranding, consolidation and building • Corporate costs reduced significantly • Closed German operations • Rationalised head office staffing • Migrated to technology-enabled virtual office • IgM program progressing via alliance • PAT-SC1 alliance progressing on track • PAT-SM6 manufacturing and clinical trial remain on hold • Deoxymab program licensed from Yale University • Novel, first-in-class nuclear penetrating antibodies • Multiple possible development paths • Development progressing on time and on budget Annual General Meeting 2016 5

Experienced leadership team • Board • John Read Chairman • James Campbell CEO & Managing Director • Mike Stork Non-Executive Director • Suzy Jones Non-Executive Director • Management • Dr James Campbell CEO & Managing Director • Melanie Leydin CFO & Company Secretary • Dr Deanne Greenwood VP, Business Development & IP • Valentina Dubljevic VP, Scientific & Clinical Development Annual General Meeting 2016 6

Development pipeline Product Discovery Preclinical Phase I Phase 2a (Target) PAT-SC1 Chinese rights Gastric Cancer (CD55) out-licensed PAT-SM6 Melanoma Multiple Myeloma Trial Deferred (GRP78) PAT-LM1 Licensing Solid Tumours candidate (NONO) Deoxymab Licensed from 3E10 Yale University (DNA) Deoxymab5 Licensed from Yale University C6 (DNA) Annual General Meeting 2016 7

IgM assets • Patrys’ IgM assets have shown anti-tumour activity in mice and in humans have shown a very good safety profile and signals of clinical efficacy • Natural human antibodies can be combined with existing chemotherapeutic treatments potentially without any cumulative toxicology effects • The Chinese rights for PAT-SM1 have been licensed to Hefei Co-Source, which is progressing well with its development plans. The Joint Development Committee met in October, and is pleased with progress to date. This alliance provides possible future milestone payments and royalties • Manufacturing of PAT-SM6 and a possible clinical trial remain on hold until non-dilutive funding for this program can be obtained • Ongoing BD efforts for all IgM assets Annual General Meeting 2016 8

Introducing Deoxymab 3E10 • Deoxymab 3E10 is a nuclear-penetrating lupus anti-DNA autoantibody with proven utility as a molecular delivery vehicle • 3E10 has previously been used in Phase 1 clinical trial for lupus • Anti-cancer application licensed from Yale University • First in class mechanism of action – potentially major advantages over PARP inhibitors • Patrys is developing di-scFv to target solid tumors, particularly glioblastoma, pancreatic, breast and ovarian Annual General Meeting 2016 9

Deoxymab 3E10 – Mechanism of action Annual General Meeting 2016 10

Research partnered with Yale University • James E. Hansen, MD (Principal Investigator) • Assistant Professor, Department of Therapeutic Radiology, Yale School of Medicine • Physician-scientist and practicing radiation oncologist specializing in treatment of cancers of the brain, head and neck, lung, skin, and lymphatic system • 12+ years of experience working with 3E10 and other cell-penetrating Abs • Lead inventor on patents pertaining to use of Deoxymabs against cancer • Jiangbing Zhou, PhD (Collaborator) • Assistant Professor, Department of Neuro- surgery and Biomedical Engineering, Yale School of Medicine • Expert in animal models for drug candidate testing, with special expertise in brain tumor models Annual General Meeting 2016 11

Multiple development paths for 3E10 Deoxymab 3E10 Combina4on with radia4on Single agent for targeted Combina4on with chemotherapy therapy for radioresistant therapy of malignancies for chemo-resistant tumors and/ tumors and/or to reduce the with defects in DNA repair, or to reduce the required dose of required dose of radia4on such as BRCA or PTEN- chemotherapy deficient cancers Annual General Meeting 2016 12

Deoxymab 3E10 enhances radiotherapy 3E10 scFv radiosensi4ses U87 human glioma cells, but is not toxic to unirradiated cells Hansen et al. , (2012) Science Transla.onal Medicine , 4(157): 157ra142. Annual General Meeting 2016 13

Deoxymab 3E10 enhances chemotherapy Using U87 human glioma cells Deoxymab 3E10 enhances chemotherapy which causes DNA damage (Doxorubicin), but not chemotherapy that doesn’t affect DNA (Paclitaxel) Doxorubicin Paclitaxel % Dead cells % Dead cells nM nM Hansen et al. , (2012) Science Transla.onal Medicine , 4(157): 157ra142. Annual General Meeting 2016 14

Deoxymab 3E10 single agent efficacy Deoxymab 3E10 decreases tumour growth in BRCA2- deficient CAPAN-1(pancrea4c) xenograis Noble et al. (2015). Cancer Research . 75(11): 2285-91. Annual General Meeting 2016 15

Deoxymab 3E10 development milestones File IND 9 Pre-IND Mee7ng with FDA 8 File Orphan Drug Applica7on 7 Safety Pharmacology Completed 6 Tox Program Completed 5 Stability completed 4 Comple7on of cGMP Manufacturing 3 Potency Studies at Yale 2 Complete An7body Humaniza7on 1 Annual General Meeting 2016 16

The year ahead ✓ • Comple4on of in silico design and op4miza4on of Deoxymab 3E10 ✓ • Preclinical tes4ng of mul4ple Deoxymab 3E10 candidates • Lead candidate selec4on for Deoxymab 3E10 program • Preclinical data and publica4ons on Abs and targets • Ongoing development of PAT-SC1 (via strategic alliance) • Addi4onal alliances and collabora4ons Annual General Meeting 2016 17

Further information Dr James Campbell, CEO and Managing Director Ph: +61 3 9670 3273 Email: info@patrys.com Website: www.patrys.com Annual General Meeting 2016 19